Last checked at 4 Mar 2020 07:00
04 March 2020
N4 Pharma plc
("N4 Pharma", the "Company" or the "Group")
Posting of Annual Report and Accounts and Notice of AGM
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, announces that its Annual Report and Accounts for the year ended 31 December 2019 and Notice of the Annual General Meeting will be posted to shareholders later today, and are available on the Company's website at www.n4pharma.com.
The Company's Annual General Meeting will be held at 1:30 p.m. on 31 March 2020 at the offices of Shakespeare Martineau LLP, 6th Floor, 60 Gracechurch Street, London, EC3V 0HR.
Enquiries:
N4 Pharma Plc Nigel Theobald, CEO
|
Via Scott PR |
Allenby Capital Limited James Reeve/Asha Chotai
| Tel: +44(0)203 328 5656 |
Scott PR Georgia Smith
| Tel: +44(0)1477 539 539 |
About N4 Pharma
N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for cancer and vaccine treatments using its unique silica nanoparticle delivery system called Nuvec®.
N4 Pharma's business model is to partner with companies developing novel antigens for cancer and vaccine treatments to use Nuvec® as the delivery vehicle to get their antigen into cells to express the protein needed for the required immunity. As these products progress through pre clinical and clinical programs, N4 Pharma will seek to receive up front payments, milestone payments and ultimately royalty payments once products reach the market.